Sonova stock holds steady as investors track earnings

Sonova Holding AG (ISIN CH0012549785) is a Swiss hearing-care group whose latest publicly available operating figures still frame the stock on 11 August 2026. The company reported CHF 3.87 billion in sales for fiscal 2025-26, up 6.6% at constant exchange rates, with EBITA of CHF 759.8 million and net profit of CHF 581.9 million.

Fiscal 2025-26 sets the base

Those fiscal 2025-26 numbers matter because they show the scale of the business before any newer catalyst enters the tape. Sales reached CHF 3.87 billion, EBITA came in at CHF 759.8 million, and net profit totaled CHF 581.9 million, giving investors three dated reference points for valuation and margin work.

The comparison is straightforward: revenue grew 6.6% year on year at constant exchange rates, which is the key growth marker in the latest annual figures. That kind of rate is enough to keep the market focused on whether Sonova can extend margin discipline as the top line expands.

Margins and cash flow

Sonova also said it delivered a free cash flow figure of CHF 589.9 million in fiscal 2025-26, a number that helps explain why the balance sheet and cash conversion remain central to the equity story. For a medtech stock, cash generation often matters as much as headline sales growth, especially when earnings are already above CHF 500 million.

The annual report also gives a clearer operating frame: EBITA of CHF 759.8 million against sales of CHF 3.87 billion implies a margin profile that investors can compare with earlier years and with other hearing-care names. The latest report therefore places the emphasis on execution rather than on a single quarter spike.

Zurich listing context

Sonova trades on the SIX Swiss Exchange, where the market typically prices Swiss medtech names in Swiss francs and reacts to report cadence, margin changes, and cash flow conversion. For this stock, the immediate numbers that still matter are the fiscal 2025-26 sales of CHF 3.87 billion, EBITA of CHF 759.8 million, and free cash flow of CHF 589.9 million.

That combination gives the shares a clear analytical base even without a fresh release in the current search set. Investors looking at Sonova stock will mainly compare the 6.6% constant-currency sales increase with the profitability and cash figures from the same fiscal year.

Hearing systems drive revenue

Sonova's hearing systems and hearing instruments remain the core product lines behind the annual revenue figure. In fiscal 2025-26, the company's sales mix supported CHF 3.87 billion in revenue, which is the cleanest product-linked number available in the latest report context.

The product layer matters because it connects end demand with the operating result. A business that can convert CHF 3.87 billion in sales into CHF 759.8 million of EBITA is being judged on product mix, pricing, and reimbursement trends as much as on unit growth.

Stock level remains the focus

Without a fresh market quote in the current source set, the most recent evidenced market context is the Zurich listing itself and the fiscal 2025-26 report metrics that continue to frame expectations. Sonova stock therefore reads through the lens of CHF 3.87 billion sales, CHF 759.8 million EBITA, and CHF 589.9 million free cash flow until the next dated update appears in the market data.